Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | ACE | P12821 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16289258 | 1.00 | SMN1; SMN2 (0.34) | SMN1; SMN2HDAC2HDAC3HDAC1HDAC8 | |
| SCHEMBL16287759 | 0.89 | KMT2A (0.37) | SMN1; SMN2HDAC2ALDH1A1LMNAPOLB | |
| SCHEMBL15083256 | 0.89 | KMT2A (0.37) | SMN1; SMN2HDAC2ALDH1A1LMNAPOLB | |
| SCHEMBL15083151 | 0.85 | CASP1 (0.37) | SMN1; SMN2ACE | |
| SCHEMBL16288691 | 0.85 | CASP1 (0.37) | SMN1; SMN2ACE | |
| SCHEMBL16289740 | 0.82 | ACE (0.39) | ACECTSKPOLB | |
| SCHEMBL15083168 | 0.82 | ACE (0.39) | ACECTSKPOLB | |
| SCHEMBL15083125 | 0.81 | EPHX2 (0.39) | SMN1; SMN2HDAC2ALDH1A1 | |
| SCHEMBL16288601 | 0.81 | EPHX2 (0.39) | SMN1; SMN2HDAC2ALDH1A1 | |
| SCHEMBL15083070 | 0.80 | KMT2A (0.32) | ALDH1A1LMNAPOLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12415835-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-16 | — | — | US | disclosed |
| US-20240166689-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-23 | — | — | US | disclosed |
| US-11891457-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-06 | — | — | US | disclosed |
| EP-3974563-A1 | CYCLIC PEPTIDES | Chugai Seiyaku Kabushiki Kaisha (JP) | 2022-03-30 | — | — | EP | disclosed |
| EP-2813512-B1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2021-03-31 | — | — | EP | disclosed |
| EP-2813512-B1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2021-03-31 | — | — | EP | disclosed |
| US-20210061860-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2021-03-04 | — | — | US | disclosed |
| US-20210061860-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2021-03-04 | — | — | US | disclosed |
| US-20160311858-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-10-27 | — | — | US | disclosed |
| US-20160311858-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-10-27 | — | — | US | disclosed |
| US-9409952-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-08-09 | — | — | US | disclosed |
| US-9409952-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-08-09 | — | — | US | disclosed |
| US-9409952-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-08-09 | — | — | US | disclosed |
| US-20150080549-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-03-19 | — | — | US | disclosed |
| US-20150080549-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-03-19 | — | — | US | disclosed |
| US-20150080549-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-03-19 | — | — | US | disclosed |
| EP-2813512-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | Chugai Seiyaku Kabushiki Kaisha (JP) | 2014-12-17 | — | — | EP | disclosed |
| EP-2813512-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | Chugai Seiyaku Kabushiki Kaisha (JP) | 2014-12-17 | — | — | EP | disclosed |
| WO-2013100132-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | 中外製薬株式会社 (JP) | 2013-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11891457-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | SMN1; SMN2 4620/4885HDAC2 2405/4885HDAC3 1300/4885 |
| US-20210061860-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | VIP, NGLY1, GLP1R | SMN1; SMN2 4620/4885HDAC2 2405/4885HDAC3 1300/4885 |
| US-20240166689-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | VIP, NGLY1, GLP1R | SMN1; SMN2 4620/4885HDAC2 2405/4885HDAC3 1300/4885 |
| US-20160311858-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | VIP, NGLY1, GLP1R | SMN1; SMN2 4620/4885HDAC2 2405/4885HDAC3 1300/4885 |
| US-20150080549-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | VIP, NGLY1, GLP1R | SMN1; SMN2 4620/4885HDAC2 2405/4885HDAC3 1300/4885 |
| US-12415835-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | SMN1; SMN2 4620/4885HDAC2 2405/4885HDAC3 1300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.